Richard S.E. Keefe has not added Biography.
If you are Richard S.E. Keefe and would like to personalize this page please email our Author Liaison for assistance.
Sensory acuity and reasoning in delusional disorder.
Comprehensive psychiatry May-Jun, 2002 | Pubmed ID: 11994833
Source-monitoring deficits for self-generated stimuli in schizophrenia: multinomial modeling of data from three sources.
Schizophrenia research Sep, 2002 | Pubmed ID: 12165376
Source monitoring improvement in patients with schizophrenia receiving antipsychotic medications.
Psychopharmacology Sep, 2003 | Pubmed ID: 12759802
Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale.
Schizophrenia bulletin , 2003 | Pubmed ID: 12908660
Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness.
The Journal of clinical psychiatry Mar, 2004 | Pubmed ID: 15096076
The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery.
Schizophrenia research Jun, 2004 | Pubmed ID: 15099610
Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol.
The American journal of psychiatry Jun, 2004 | Pubmed ID: 15169686
Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria.
Biological psychiatry Sep, 2004 | Pubmed ID: 15336511
Defining a cognitive function decrement in schizophrenia.
Biological psychiatry Mar, 2005 | Pubmed ID: 15780858
Antipsychotic drug effects on brain morphology in first-episode psychosis.
Archives of general psychiatry Apr, 2005 | Pubmed ID: 15809403
A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia.
Schizophrenia bulletin Jan, 2005 | Pubmed ID: 15888422
The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome.
Schizophrenia research Dec, 2005 | Pubmed ID: 16125372
Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis.
Biological psychiatry Jan, 2006 | Pubmed ID: 16140282
Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial.
Schizophrenia research Dec, 2005 | Pubmed ID: 16171976
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
The New England journal of medicine Sep, 2005 | Pubmed ID: 16172203
One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia.
Schizophrenia research Jan, 2006 | Pubmed ID: 16202565
Measuring outcome priorities and preferences in people with schizophrenia.
The British journal of psychiatry : the journal of mental science Dec, 2005 | Pubmed ID: 16319405
The relationship of the Brief Assessment of Cognition in Schizophrenia (BACS) to functional capacity and real-world functional outcome.
Journal of clinical and experimental neuropsychology Feb, 2006 | Pubmed ID: 16484097
The Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity.
The American journal of psychiatry Mar, 2006 | Pubmed ID: 16513863
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.
The American journal of psychiatry Apr, 2006 | Pubmed ID: 16585434
Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic.
The American journal of psychiatry Apr, 2006 | Pubmed ID: 16585435
Optimization of a multinomial model for investigating hallucinations and delusions with source monitoring.
Schizophrenia research Jul, 2006 | Pubmed ID: 16626938
Baseline neurocognitive deficits in the CATIE schizophrenia trial.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology Sep, 2006 | Pubmed ID: 16641947
Insight in first-episode psychosis.
Psychological medicine Oct, 2006 | Pubmed ID: 16740175
Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial.
Psychiatric services (Washington, D.C.) Aug, 2006 | Pubmed ID: 16870959
A longitudinal study of neurocognitive function in individuals at-risk for psychosis.
Schizophrenia research Dec, 2006 | Pubmed ID: 16930949
Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.
The American journal of psychiatry Dec, 2006 | Pubmed ID: 17151158
NCAM1 and neurocognition in schizophrenia.
Biological psychiatry Apr, 2007 | Pubmed ID: 17161382
Risperidone and cognitive function in children with disruptive behavior disorders.
Biological psychiatry Aug, 2007 | Pubmed ID: 17210137
Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.
The American journal of psychiatry Mar, 2007 | Pubmed ID: 17329466
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
The American journal of psychiatry Mar, 2007 | Pubmed ID: 17329467
Validation of the French version of the BACS (the brief assessment of cognition in schizophrenia) among 50 French schizophrenic patients.
European psychiatry : the journal of the Association of European Psychiatrists Sep, 2007 | Pubmed ID: 17434715
AKT1 and neurocognition in schizophrenia.
The Australian and New Zealand journal of psychiatry Feb, 2007 | Pubmed ID: 17464696
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
Archives of general psychiatry Jun, 2007 | Pubmed ID: 17548746
How should DSM-V criteria for schizophrenia include cognitive impairment?
Schizophrenia bulletin Jul, 2007 | Pubmed ID: 17567627
Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.
The American journal of psychiatry Jul, 2007 | Pubmed ID: 17606658
Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology May, 2008 | Pubmed ID: 17625502
Cognition as an outcome measure in schizophrenia.
The British journal of psychiatry. Supplement Aug, 2007 | Pubmed ID: 18019044
Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study.
The American journal of psychiatry Feb, 2008 | Pubmed ID: 18172017
The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization.
The American journal of psychiatry Feb, 2008 | Pubmed ID: 18172018
The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity.
The American journal of psychiatry Feb, 2008 | Pubmed ID: 18172019
Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia.
The journal of behavioral health services & research Apr, 2008 | Pubmed ID: 18246429
Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia.
Journal of the International Neuropsychological Society : JINS Mar, 2008 | Pubmed ID: 18282319
Cognitive deficits in patients with schizophrenia: effects and treatment.
The Journal of clinical psychiatry , 2007 | Pubmed ID: 18284272
The neuregulin 1 promoter polymorphism rs6994992 is not associated with chronic schizophrenia or neurocognition.
American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics Oct, 2008 | Pubmed ID: 18286587
Relationship of cognition and psychopathology to functional impairment in schizophrenia.
The American journal of psychiatry Aug, 2008 | Pubmed ID: 18450928
What CATIE found: results from the schizophrenia trial.
Psychiatric services (Washington, D.C.) May, 2008 | Pubmed ID: 18451005
Should cognitive impairment be included in the diagnostic criteria for schizophrenia?
World psychiatry : official journal of the World Psychiatric Association (WPA) Feb, 2008 | Pubmed ID: 18458774
Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS).
Schizophrenia research Jul, 2008 | Pubmed ID: 18495435
Implementation considerations for multisite clinical trials with cognitive neuroscience tasks.
Schizophrenia bulletin Jul, 2008 | Pubmed ID: 18495645
Abbreviated neuropsychological assessment in schizophrenia: prediction of different aspects of outcome.
Journal of clinical and experimental neuropsychology May, 2009 | Pubmed ID: 18720182
Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America Double Blind Treatment Study.
Schizophrenia research Oct, 2008 | Pubmed ID: 18774696
Extrapyramidal side-effects of antipsychotics in a randomised trial.
The British journal of psychiatry : the journal of mental science Oct, 2008 | Pubmed ID: 18827289
Development and psychometric performance of the schizophrenia objective functioning instrument: an interviewer administered measure of function.
Schizophrenia research Feb, 2009 | Pubmed ID: 19013769
CMINDS does not have identical tests to the CATIE and MATRICS batteries. Commentary on O'Halloran et al.
Schizophrenia research Feb, 2009 | Pubmed ID: 19013770
Results of phase 3 of the CATIE schizophrenia trial.
Schizophrenia research Jan, 2009 | Pubmed ID: 19027269
Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis.
European journal of human genetics : EJHG Jul, 2009 | Pubmed ID: 19156168
A genome-wide investigation of SNPs and CNVs in schizophrenia.
PLoS genetics Feb, 2009 | Pubmed ID: 19197363
Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology Jul, 2009 | Pubmed ID: 19339966
Psychosocial factors in the neurobiology of schizophrenia: a selective review.
Annals of the Academy of Medicine, Singapore May, 2009 | Pubmed ID: 19521639
Measuring memory-prediction errors and their consequences in youth at risk for schizophrenia.
Annals of the Academy of Medicine, Singapore May, 2009 | Pubmed ID: 19521641
Memory-prediction errors and their consequences in schizophrenia.
Neuropsychology review Sep, 2009 | Pubmed ID: 19575296
Cognition and schizophrenia: is there a role for cognitive assessments in diagnosis and treatment?
Psychiatry (Edgmont (Pa. : Township)) Dec, 2008 | Pubmed ID: 19724777
The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial.
Schizophrenia research Nov, 2009 | Pubmed ID: 19766459
A brief cognitive assessment tool for schizophrenia: construction of a tool for clinicians.
Schizophrenia bulletin May, 2011 | Pubmed ID: 19776205
Anticipating DSM-V: opportunities and challenges for cognition and psychosis.
Schizophrenia bulletin Jan, 2010 | Pubmed ID: 19923191
Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: a 30-year study.
The American journal of psychiatry Feb, 2010 | Pubmed ID: 20048021
Circumstances under which practice does not make perfect: a review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology Apr, 2010 | Pubmed ID: 20090669
Report from the working group conference on multisite trial design for cognitive remediation in schizophrenia.
Schizophrenia bulletin Sep, 2011 | Pubmed ID: 20194249
Etiological and clinical features of childhood psychotic symptoms: results from a birth cohort.
Archives of general psychiatry Apr, 2010 | Pubmed ID: 20368509
The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?
Schizophrenia bulletin Nov, 2011 | Pubmed ID: 20410237
The Schizophrenia Cognition Rating Scale: validation of an interview-based assessment of cognitive functioning in Asian patients with schizophrenia.
Psychiatry research Jun, 2010 | Pubmed ID: 20451258
No association of the serotonin transporter polymorphisms 5-HTTLPR and RS25531 with schizophrenia or neurocognition.
American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics Jul, 2010 | Pubmed ID: 20468059
Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis.
Archives of general psychiatry Jun, 2010 | Pubmed ID: 20530007
The Cognitive Assessment Interview (CAI): development and validation of an empirically derived, brief interview-based measure of cognition.
Schizophrenia research Aug, 2010 | Pubmed ID: 20542412
Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.
The Journal of clinical psychiatry Mar, 2011 | Pubmed ID: 20816031
Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study.
The Journal of clinical psychiatry Nov, 2010 | Pubmed ID: 20816042
Differential effects of emotional information on interference task performance across the life span.
Frontiers in aging neuroscience , 2010 | Pubmed ID: 20953250
Missing the sweet spot disengagement in schizophrenia.
Psychiatry (Edgmont (Pa. : Township)) Jul, 2006 | Pubmed ID: 20975816
Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial.
Schizophrenia research Feb, 2011 | Pubmed ID: 21075600
Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology Feb, 2011 | Pubmed ID: 21107309
Criminal justice system involvement among people with schizophrenia.
Community mental health journal Dec, 2011 | Pubmed ID: 21113799
Failures in learning-dependent predictive perception as the key cognitive vulnerability to psychosis in schizophrenia.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology Jan, 2011 | Pubmed ID: 21116261
A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia.
Biological psychiatry Mar, 2011 | Pubmed ID: 21145041
The MCCB impairment profile for schizophrenia outpatients: results from the MATRICS psychometric and standardization study.
Schizophrenia research Mar, 2011 | Pubmed ID: 21159492
Methodological issues in negative symptom trials.
Schizophrenia bulletin Mar, 2011 | Pubmed ID: 21270473
Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone.
Schizophrenia research Apr, 2011 | Pubmed ID: 21277745
Bifactor and item response theory analyses of interviewer report scales of cognitive impairment in schizophrenia.
Psychological assessment Mar, 2011 | Pubmed ID: 21381848
Comprehensive model of how reality distortion and symptoms occur in schizophrenia: could impairment in learning-dependent predictive perception account for the manifestations of schizophrenia?
Psychiatry and clinical neurosciences Jun, 2011 | Pubmed ID: 21447049
Longitudinal consent-related abilities among research participants with schizophrenia: results from the CATIE study.
Schizophrenia research Aug, 2011 | Pubmed ID: 21561740
Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD.
The American journal of psychiatry Aug, 2011 | Pubmed ID: 21572163
Substance use and schizophrenia: adverse correlates in the CATIE study sample.
Schizophrenia research Nov, 2011 | Pubmed ID: 21872443
The Singapore flagship programme in translational and clinical research in psychosis.
Early intervention in psychiatry Nov, 2011 | Pubmed ID: 22032547
Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far?
Schizophrenia bulletin Mar, 2013 | Pubmed ID: 22114098
Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia.
Schizophrenia research Apr, 2012 | Pubmed ID: 22169248
Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data.
Schizophrenia bulletin May, 2013 | Pubmed ID: 22290266
The Cognitive Assessment Interview (CAI): reliability and validity of a brief interview-based measure of cognition.
Schizophrenia bulletin May, 2013 | Pubmed ID: 22328641
Clues to the cognitive and perceptual origins of social isolation and psychosis in schizophrenia.
The American journal of psychiatry Apr, 2012 | Pubmed ID: 22476674
A randomized controlled trial of allopurinol vs. placebo added on to antipsychotics in patients with schizophrenia or schizoaffective disorder.
Schizophrenia research Jun, 2012 | Pubmed ID: 22483162
Feasibility and pilot efficacy results from the multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) randomized controlled trial.
The Journal of clinical psychiatry Jul, 2012 | Pubmed ID: 22687548
Validation of a clinician questionnaire to assess reasons for antipsychotic discontinuation and continuation among patients with schizophrenia.
Psychiatry research Dec, 2012 | Pubmed ID: 22841345
Persistent cannabis users show neuropsychological decline from childhood to midlife.
Proceedings of the National Academy of Sciences of the United States of America Oct, 2012 | Pubmed ID: 22927402
Cognitive impairment in schizophrenia.
Handbook of experimental pharmacology , 2012 | Pubmed ID: 23027411
Standardizing the use of the Continuous Performance Test in schizophrenia research: a validation study.
Schizophrenia research Dec, 2012 | Pubmed ID: 23040735
How specific are negative symptoms and cognitive impairment in schizophrenia? An analysis of PANSS and SCoRS.
Cognitive neuropsychiatry May, 2013 | Pubmed ID: 23145794
Formulation of the age-education index: measuring age and education effects in neuropsychological performance.
Psychological assessment Mar, 2013 | Pubmed ID: 23148648
The course of cognitive functioning over six months in individuals at clinical high risk for psychosis.
Psychiatry research Apr, 2013 | Pubmed ID: 23159196
Applicability of the MATRICS Consensus Cognitive Battery in Singapore.
The Clinical neuropsychologist , 2013 | Pubmed ID: 23362823
Interview-based assessment of cognition in schizophrenia: applicability of the Schizophrenia Cognition Rating Scale (SCoRS) in different phases of illness and settings of care.
Schizophrenia research May, 2013 | Pubmed ID: 23510596
Cognition in schizophrenia: summary Nice Consultation Meeting 2012.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology Aug, 2013 | Pubmed ID: 23684476
Neuropsychological impairments in schizophrenia and psychotic bipolar disorder: findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study.
The American journal of psychiatry Nov, 2013 | Pubmed ID: 23771174
Altered Striatal Functional Connectivity in Subjects With an At-Risk Mental State for Psychosis.
Schizophrenia bulletin Jul, 2013 | Pubmed ID: 23861539
Defining a clinically meaningful effect for the design and interpretation of randomized controlled trials.
Innovations in clinical neuroscience May, 2013 | Pubmed ID: 23882433
Brief Assessment of Cognition in Schizophrenia: Normative Data in an English-Speaking Ethnic Chinese Sample.
Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists Aug, 2013 | Pubmed ID: 23912998
Schizophrenia is a cognitive illness: time for a change in focus.
JAMA psychiatry Oct, 2013 | Pubmed ID: 23925787
Social cognition as a mediator between neurocognition and functional outcome in individuals at clinical high risk for psychosis.
Schizophrenia research Nov, 2013 | Pubmed ID: 24012459
Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia.
Schizophrenia research Nov, 2013 | Pubmed ID: 24028744
Neuropsychological decline in schizophrenia from the premorbid to the postonset period: evidence from a population-representative longitudinal study.
The American journal of psychiatry Jan, 2014 | Pubmed ID: 24030246
Microvascular abnormality in schizophrenia as shown by retinal imaging.
The American journal of psychiatry Dec, 2013 | Pubmed ID: 24030514
Preserved working memory and altered brain activation in persons at risk for psychosis.
The American journal of psychiatry Nov, 2013 | Pubmed ID: 24077560
Elevated Antisaccade Error Rate as an Intermediate Phenotype for Psychosis Across Diagnostic Categories.
Schizophrenia bulletin Sep, 2013 | Pubmed ID: 24080895
Unraveling the relationship between obesity, schizophrenia and cognition.
Schizophrenia research Dec, 2013 | Pubmed ID: 24119725
The Longitudinal Youth at Risk Study (LYRIKS)--an Asian UHR perspective.
Schizophrenia research Dec, 2013 | Pubmed ID: 24139196
Validation of the Persian version of the brief assessment of cognition in schizophrenia in patients with schizophrenia and healthy controls.
Psychiatry and clinical neurosciences Feb, 2014 | Pubmed ID: 24552637
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved